Literature DB >> 12456938

Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States.

Vitali Pool1, M Miles Braun, John M Kelso, Gina Mootrey, Robert T Chen, John W Yunginger, Robert M Jacobson, Paul M Gargiullo.   

Abstract

OBJECTIVE: Anaphylaxis after immunization, although rare, is serious and potentially life-threatening. Understanding risk factors for this reaction is therefore important. Gelatin is added to many vaccines as a heat stabilizer. Japanese researchers have demonstrated a strong association between immediate hypersensitivity reactions to measles, mumps, rubella, varicella, and Japanese encephalitis immunizations and subsequent detection of anti-gelatin immunoglobulin E (IgE) antibodies. They suggested that previous receipt by these patients of diphtheria-tetanus-acellular pertussis vaccines with trace amounts of gelatin was responsible for the sensitization. We aimed to assess whether a similar association exists for vaccinees in the United States who reported anaphylaxis after receipt of measles-mumps-rubella (MMR) or measles vaccines and to review recent trends in reporting of hypersensitivity reactions.
METHODS: We conducted a retrospective case-control study. Cases of anaphylaxis that met a predefined case definition were identified from the US Vaccine Adverse Event Reporting System (VAERS). Mayo Clinic patients who received MMR vaccine uneventfully served as controls. The study subjects were interviewed to obtain the history of allergies. Sera from study subjects and their matched controls were tested for IgE antibodies to gelatin, whole egg, and vaccine viral antigens using solid-phase radioimmunoassay. Data from the Biologics Surveillance System on annual numbers of doses of MMR and varicella vaccines distributed in the United States were used to evaluate possible changes in reporting of selected allergic adverse events.
RESULTS: Fifty-seven study subjects were recruited into the study and interviewed. Of these, 22 provided serum samples for IgE testing. Twenty-seven subjects served as a comparison group and provided a sample for IgE testing; 21 of these completed an allergy history questionnaire. Self-reported history of food allergies was present more frequently in the interviewed study subjects than in the controls, whereas the proportions of people with other characteristics were similar in both groups. None of the interviewed people had a history of food allergy to gelatin. The level of anti-gelatin IgE antibodies was significantly higher among study subjects than among controls, whereas the levels of IgE antibodies against egg and all 3 viral antigens did not differ significantly. Of 22 study subjects, 6 (27%) tested positive for anti-gelatin IgE, whereas none of the 27 controls did. The rate of anaphylactic reactions reported to VAERS after measles virus-containing immunization in the United States between 1991 and 1997 is 1.8 per 1 million doses distributed. No substantial increase in the number of reported allergic events after frequently used gelatin containing MMR and varicella vaccines could be observed during the first 4 years (1997-2000) since the introduction of diphtheria-tetanus-acellular pertussis vaccines for use in infancy.
CONCLUSION: Anaphylactic reactions to MMR in the United States are rare. The reporting rate has the same order of magnitude as estimates from other countries. Almost one fourth of patients with reported anaphylaxis after MMR seem to have hypersensitivity to gelatin in the vaccine. They may be at higher risk of developing anaphylaxis to subsequent doses of other gelatin-containing vaccines. These people should seek an allergy evaluation before such immunization.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12456938     DOI: 10.1542/peds.110.6.e71

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  25 in total

1.  Anaphylaxis as an adverse event following immunisation.

Authors:  Michel Erlewyn-Lajeunesse; Jan Bonhoeffer; Jens U Ruggeberg; Paul T Heath
Journal:  J Clin Pathol       Date:  2007-05-04       Impact factor: 3.411

2.  Measles, mumps, rubella (MMR) vaccine.

Authors:  A P Dubey; S Banerjee
Journal:  Indian J Pediatr       Date:  2003-07       Impact factor: 1.967

3.  The human papillomavirus vaccine and risk of anaphylaxis.

Authors:  Neal A Halsey
Journal:  CMAJ       Date:  2008-09-01       Impact factor: 8.262

Review 4.  Immune-mediated adverse reactions to vaccines.

Authors:  Cosby A Stone; Christine R F Rukasin; Thomas M Beachkofsky; Elizabeth J Phillips
Journal:  Br J Clin Pharmacol       Date:  2019-11-05       Impact factor: 4.335

5.  The diagnosis and management of egg allergy.

Authors:  Ralf G Heine; Nora Laske; David J Hill
Journal:  Curr Allergy Asthma Rep       Date:  2006-03       Impact factor: 4.806

6.  Bovine and porcine gelatin sensitivity in children sensitized to milk and meat.

Authors:  Jelena Bogdanovic; Neal A Halsey; Robert A Wood; Robert G Hamilton
Journal:  J Allergy Clin Immunol       Date:  2009-08-08       Impact factor: 10.793

7.  Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990-2016.

Authors:  John R Su; Pedro L Moro; Carmen S Ng; Paige W Lewis; Maria A Said; Maria V Cano
Journal:  J Allergy Clin Immunol       Date:  2019-01-14       Impact factor: 10.793

Review 8.  Current understanding of egg allergy.

Authors:  Jean-Christoph Caubet; Julie Wang
Journal:  Pediatr Clin North Am       Date:  2011-04       Impact factor: 3.278

9.  Development and distribution of mast cells and neuropeptides in human fetus duodenum.

Authors:  Xiao-Yu Chen; Xue-Mei Jia; You-Su Jia; Xiao-Rong Chen; Hui-Zhu Wang; Wei-Qin Qi
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

10.  Anaphylaxis following quadrivalent human papillomavirus vaccination.

Authors:  Julia M L Brotherton; Mike S Gold; Andrew S Kemp; Peter B McIntyre; Margaret A Burgess; Sue Campbell-Lloyd
Journal:  CMAJ       Date:  2008-09-01       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.